• Explore /
  • Poster
  • / Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update.

Phase I study with pegylated human IL-10 (AM0010) alone or in combination with anti-PD-1 or FOLFOX-immune biomarker update.

Abstract Poster

Authors

null

Aung Naing

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Aung Naing, Jeffrey R. Infante, J. Randolph Hecht, Kyriakos P. Papadopoulos, Deborah Jean Lee Wong, Karen A. Autio, Gerald Steven Falchook, Manish R. Patel, Patrick Alexander Ott, Amita Patnaik, Johanna C. Bendell, Peter Van Vlasselaer, David S. Hong, Nizar M. Tannir, Martin Oft

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Clinical Trials

Clinical Trial Registration Number

NCT02009449

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 157)

DOI

10.1200/JCO.2017.35.7_suppl.157

Abstract #

157

Poster Bd #

H6

Abstract Disclosures

Similar Posters

First Author: Jacob J. Adashek

First Author: Aung Naing

Poster

2017 ASCO Annual Meeting

PEGylated human IL-10 (AM0010) monotherapy in refractory metastatic colorectal cancer.

PEGylated human IL-10 (AM0010) monotherapy in refractory metastatic colorectal cancer.

First Author: Jeffrey R. Infante

First Author: Carmen Alvarez-Dominguez